Timothy N. Phoenix

This paper shows that combining GLP1R agonists with vorasidenib induces synergistic cytotoxicity in mIDH glioma by generating peroxynitrite through mitochondrial redox metabolism.

This study identifies AHCY as a key driver of epigenetic and metabolic reprogramming in ZFTA-RELA ependymomas, revealing its role in promoting tumor growth through pyrimidine synthesis and asparagine dependency.

This study identifies CD11c+ microglia as a key driver of T cell dysfunction in diffuse midline glioma through genetic and orthotopic mouse models.

This study creates a mouse model of IDH-mutant 1p/19q-codeleted oligodendroglioma and identifies genotype-specific phenotypes and molecular features.

This study shows that combining FACT and BET inhibition disrupts oncogenic transcription and extends survival in Diffuse Midline Glioma models.

The paper identifies O-mannosylation and protein maturation as therapeutic targets in BRAF fusion oncogenesis by showing their necessity for fusion-induced transformation.

This study investigates age-dependent tumor-immune interactions in pediatric cancer using mouse models and patient samples, finding that pediatric tumors have distinct immune profiles and poor response to immunotherapy, which can be improved by modulating the tumor microenvironment.

This study identifies nuclear factor I (NFI) as a driver of dysregulated purine metabolism in DIPG, showing that targeting ATIC reduces tumor progression in mice.

This study shows imipridones induce GABA accumulation in diffuse midline gliomas, which can be used for non-invasive imaging and therapy.